Skip to main content

Change location

You are currently on the Mexico (Español) website

My country is not on the list

Global

  • Bracco.com (English)

Asia

  • China (中文)
  • Japan (日本語)
  • South Korea (한국어)

Americas

  • Brazil (Português)
  • Canada (English)
  • Mexico (English)
  • Canada (Français)
  • USA (English)

Europe

  • Austria (English)
  • Belgium (English)
  • Czech Republic (English)
  • Denmark (English)
  • Finland (English)
  • France (Français)
  • Germany (Deutsch)
  • Iceland (English)
  • Italy (Italiano)
  • Luxembourg (English)
  • Norway (English)
  • Poland (English)
  • Slovakia (English)
  • Sweden (English)
  • Switzerland (English)
  • The Netherlands (English)
  • UK (English)
  • Mexico (Español)
  • Carreras
  • Media and News
  • Póngase en contacto con nosotros
    • Mexico (English)
    • Somos Bracco
    • Nuestros negocios
    • Propósito y valores
    • Nuestra historia
    • Fundación Bracco
    • Responsabilidad
    • Nuestro portafolio
      • Rayos X / (TC)
      • Medios de contraste

        • Sulfato de Bario
        • Bario TC
        • Radiologia/Fluoroscopia
        • Iomeron
        • Iopamiro
        • Cat-Bario
      • Dispositivos médicos

        • Empower CTA+
        • Accesorios Bario
      • MRI
      • Medios de contraste

        • MultiHance
        • ProHance
      • Dispositivos médicos

        • EmpowerMR
        • MustKit MR
      • CEUS
      • Medios de contraste

        • Sonovue
    • Medicina nuclear
      • Cardiología intervencionista
      • Medios de contraste

        • Iomeron
        • Iopamiro
      • Dispositivos médicos

        • ACIST CVi
    • Cardiología
    • Soluciones digitales
    • Oncología
    • Cardiology
    • Futuro digital
    • I+D
    • Los centros de Bracco
    • Herencia científica y patentes
    • Education
    • Proyectos de próxima generación
    • Bracco Global Academy
    • Nuestras alianzas
    • Eventos
    • Nuestros pilares de sustentabilidad
    • Gobernanza y transparencia
    • Sustainability report
  • Our Stories
  1. Home
  2. Nuestro portafolio
  3. Rayos X / (TC)
  4. Medios de contraste

  5. Iomeron
  6. Contrast Induced Nephropathy

Contrast Induced Nephropathy

 

1) Risk of contrast-medium-induced nephropathy in high-risk patients undergoing MDCT--a pooled analysis of two randomized trials.

 

Thomsen HS, Morcos SK. Eur Radiol. 2009 Apr;19(4):891-7. Epub 2008 Nov 11.

 

View

 

 

2) ESUR guidelines on contrast media.

 

Thomsen HS, Morcos SK; ESUR. Abdom Imaging. 2006 Mar-Apr;31(2):131-40.

 

View

 

 

3) The ACTIVE Trial: comparison of the effects on renal function of iomeprol-400 and iodixanol-320 in patients with chronic kidney disease undergoing abdominal computed tomography.

 

Thomsen HS, Morcos SK, Erley CM, Grazioli L, Bonomo L, Ni Z, Romano L; Investigators in the Abdominal Computed Tomography: IOMERON 400 Versus VISIPAQUE 320 Enhancement (ACTIVE) Study.Invest Radiol. 2008 Mar;43(3):170-8.

 

View

 

 

4) Choice of contrast medium in patients with impaired renal function undergoing percutaneous coronary intervention.

 

Wessely R, Koppara T, Bradaric C, Vorpahl M, Braun S, Schulz S, Mehilli J, Schömig A, Kastrati A; Contrast Media and Nephrotoxicity Following Coronary Revascularization by Angioplasty Trial Investigators. Circ Cardiovasc Interv. 2009 Oct;2(5):430-7. Epub 2009 Sep 22.

 

View

Please login to DocCheck
to view our products

Register here Forgot your password?

The Bracco Group is an international group of highly specialized companies.
We are an active part of the healthcare sector, and a global leader in diagnostic imaging.

  • Somos Bracco
  • Nuestro portafolio
  • Innovación
  • Aprendiendo juntos
  • Sostenibilidad
  • Our Stories
  • Farmacovigilancia/Tecnovigilancia
  • Protección de Datos

Connect with us

Via Egidio Folli 50
20134 Milan, Italy
Phone + 39 02 2177.1

  • Términos de Uso
  • Política de privacidad
  • Política de cookies
  • Aviso legal
  • for Bracco VPN users

Bracco Copyright © 2026 | Registered office: Via E. Folli, 50, 20134 Milano, Italy | Share Capital € 104.000.000 f.p. | VAT Milan Comp. Reg. n. 00825120157 | Milan REA n. 348182